Sentences with phrase «innate immunotherapeutics»

Australian biotech firm Innate Immunotherapeutics sold nearly $ 1 million in discounted shares to two US congressmen, including Representative Tom Price.

hen tiny Australian biotech firm Innate Immunotherapeutics needed to raise money last summer, it didn't issue stock on the open market.

The House Ethics Committee announced last week that it is continuing its investigation of Collins» connections with Innate Immunotherapeutics, an Australian biotech firm in which Collins is the largest shareholder.

Democratic leaders cite the House Ethics Committee's investigation of Collins» involvement with Innate Immunotherapeutics, an Austalian biotech he invested in and later touted to colleagues and Buffalo business leaders, as one reason Collins may be vulnerable.

The Office of Congressional Ethics has been probing Collins» stock transactions in a company called Innate Immunotherapeutics for months and last week said violations of federal law could have occurred.

Slaughter wrote a letter last week to the House Ethics Committee — which is investigating Collins» involvement with Innate Immunotherapeutics — criticizing Collins for not reporting his position in a separate joint venture involving the Australian biotech firm.

The Buffalo News and WGRZ say Collins» actions involving an Austrailian biotech firm, Innate Immunotherapeutics, are the subject of a probe by the...

Included in those 2016 deals was the purchase of at least $ 500,000 in stock in Innate Immunotherapeutics, an Australian biotech firm in which Collins has long been the largest investor.

«Congressman Collins» relationship with Innate Immunotherapeutics dates back more than 15 years.

But she and Holman both noted that Collins» expertise in health care comes in part from a troublesome source: his involvement in Innate Immunotherapeutics.

Public Citizen's Congress Watch, Rep. Louise M. Slaughter — a Democrat from Fairport — and several of Collins» constituents complained to that ethics office about Collins» involvement with Innate Immunotherapeutics, an Australian biotech firm whose only product is an experimental treatment for multiple sclerosis.

The largest shareholder in an obscure Australian biotech company called Innate Immunotherapeutics as well as a longtime local businessman, Collins, R - Clarence, has been part of Buffalo's business elite for decades.

Collins is the largest shareholder in that company, Innate Immunotherapeutics, which is working on an experimental treatment for secondary progressive multiple sclerosis.

In May, The News reported that the Office of Congressional Ethics is probing his investment in an obscure Australian biotech firm called Innate Immunotherapeutics.

Smierciak said he did not plan to make an issue of the fact that Collins is the subject of an Office of Congressional Ethics investigation in connection with his investment in Innate Immunotherapeutics, an Australian biotech firm that he touted for years.

Investigations by senators and the media at the time also revealed that Rep. Chris Collins, R - N.Y., told Price and at least three other House members about the stock offerings in Innate Immunotherapeutics.

Those lawmakers — Reps. Mike Conaway and John Culberson of Texas, Doug Lamborn of Colorado and Billy Long of Missouri — bought shares in Innate Immunotherapeutics.

Rep. Chris Collins (R - NY), seen in a 2016 file photo, is on the board of directors of Innate Immunotherapeutics, an Australian firm whose stock fell sharply this week.

Democratic Congresswoman Louise Slaughter is renewing calls for an investigation into stock trades surrounding Australian biotech company Innate Immunotherapeutics.

Collins cooperated with the Office of Congressional Ethics, but Innate Immunotherapeutics and Price refused to do so, according to the OCE report.

The company in the crosshairs is Innate Immunotherapeutics, of which Collins was the largest shareholder.

Rep. Louise Slaughter wrote a letter last week to the House Ethics Committee — which is investigating Rep. Chris Collins» involvement with Innate Immunotherapeutics — criticizing Collins for not reporting his position in a separate joint venture involving the Australian biotech firm.

At the recommendation of the office's report, the committee is continuing to investigate the allegations, which surround Collins» involvement with pharmaceutical company Innate Immunotherapeutics.

Despite an ethics probe into his efforts on behalf of Innate Immunotherapeutics an Australian biotech firm, which is expected to culminate in a report in the coming week, Rep. Chris Collins has stepped up his outside business interests.

Collins backers are taking heart in the fact that nowhere in the 29 - page Office of Congressional Ethics report is there any claim or any evidence that he wrote legislation on behalf of Innate Immunotherapeutics — the most explosive charge leveled against him by Rep. Louise Slaughter.

The ethics office — an independent, nonpartisan entity charged with reviewing allegations of misconduct against members, officers and staff — is concentrating on his investments in Innate Immunotherapeutics.

The largest shareholder in an obscure Australian biotech company called Innate Immunotherapeutics as well as a longtime local businessman, Rep. Chris Collins, has been part of Buffalo's business elite for decades.

Government ethics experts and a senior New York Democrat question whether Rep. Chris Collins — by far the largest shareholder in an Australian - based biotech company called Innate Immunotherapeutics — and Georgia Rep. Tom Price, Trump's health secretary nominee, bought stock in the company last year based on inside information and made a lot of moneys a result.

Collins owns more than 17 percent of shares in Innate Immunotherapeutics, according to the company's website, making him its largest stockholder.

The nature of their dealings gained attention after Price, a Georgia Republican, was grilled yesterday by Democratic senators during his confirmation hearing about purchasing stock in the company, Innate Immunotherapeutics.

Collins, who has denied any wrongdoing, was the largest shareholder of Australia's Innate Immunotherapeutics Limited and sat on the company's board of directors.

Critics, however, say Collins's incessant chatter about Innate Immunotherapeutics has blurred the line between the people's business and the congressman's private business interests.

The investigation surrounds the congressman's involvement in Australian pharmaceutical company Innate Immunotherapeutics.

Democratic Congresswoman Louise Slaughter, once again, is reiterating calls for an investigation into stock trades surrounding Australian biotech company Innate Immunotherapeutics.

Rep. Chris Collins — who is facing an Office of Congressional Ethics investigation into his investment in an obscure Australian biotech firm — walked off the House floor late yesterday afternoon, cellphone in hand, apparently talking about yet another stock trade involving that same company: Innate Immunotherapeutics.

The committee is once again taking a shot at Collins involvement in the Australian pharmaceutical company Innate Immunotherapeutics.

The bill could benefit Innate Immunotherapeutics if it ever seeks a clinical trial in the United States.

Democrats also criticized Price and Collins for trading these types of health care stocks just before voting to pass the 21st Century Cures Act, which reportedly made it easier for companies like Innate Immunotherapeutics to seek FDA approval for trials on experimental treatments.

He was also overheard at the Capitol boasting about «how many millionaires I've made in Buffalo the past few months,» an apparent reference to Innate Immunotherapeutics, an Australian firm in which Collins is a major investor.

Sources tell 2 On Your Side's Michael Wooten that the Office of Congressional Ethics probe is examining Collins» purchase of stock in a biotech company called Innate Immunotherapeutics, and the investigation is «moving swiftly».

Among those stock trades was a purchase this past August of an Australian biotech firm called Innate Immunotherapeutics.

The «stock tip» story shot back into the headlines again Tuesday after Collins mistakenly hit «reply all,» including reporter in an email intended for the head of Innate Immunotherapeutics, the company at the center of the accusations.

The renewed push from the congresswoman comes in response to a report from The Hill that Collins urged a number of his colleagues to invest in Australian bio-medical company Innate Immunotherapeutics.

Correction: June 29, 2017, 4:00 P.M.: An earlier version of this article mistakenly named Innate Immunotherapeutics as Innate Pharma.

And he probably took several of his colleagues down a couple pegs, too — Collins regularly proselytized about the company, Innate Immunotherapeutics, to fellow House Republicans and convinced at least four of them to invest, as STAT News «Damian Garde reports.